IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
Clinical trials for IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA explained in plain language.
Never miss a new study
Get alerted when new IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA trials appear
Sign up with your email to follow new studies for IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could keep rare blood disease in check
Disease control Recruiting nowThis pilot study tests efgartigimod, a drug that lowers harmful antibodies, in 15 adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare and life-threatening blood disorder. Participants receive weekly infusions for 8 weeks, then are monitored for another …
Matched conditions: IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
Phase: PHASE2 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a needle replace a machine? new study aims to simplify lifesaving iTTP treatment
Disease control Recruiting nowThis study tests whether a simpler treatment for immune thrombotic thrombocytopenic purpura (iTTP) works as well as the standard approach. Instead of daily plasma exchange (an invasive procedure), patients receive plasma infusions, immune-suppressing drugs, and caplacizumab. The …
Matched conditions: IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC